119-hr4623

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 4623 Introduced in House

    (IH) ]

<DOC>

119th CONGRESS
 1st Session
 H. R. 4623

To require direct-to-consumer advertisements for prescription drugs and 
 biological products to include truthful and not misleading pricing 
 information.

_______________________________________________________________________

 IN THE HOUSE OF REPRESENTATIVES

 July 22, 2025

 Ms. Williams of Georgia (for herself, Mr. Bacon, Ms. Craig, and Mr. 
 Steil) introduced the following bill; which was referred to the 
 Committee on Energy and Commerce, and in addition to the Committee on 
 Ways and Means, for a period to be subsequently determined by the 
 Speaker, in each case for consideration of such provisions as fall 
 within the jurisdiction of the committee concerned

_______________________________________________________________________

 A BILL

To require direct-to-consumer advertisements for prescription drugs and 
 biological products to include truthful and not misleading pricing 
 information.

 Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

 This Act may be cited as the ``Plain Prescription Prices Act''.

SEC. 2. REGULATING ADVERTISEMENTS FOR PRESCRIPTION DRUG AND BIOLOGICAL 
 PRODUCT PRICES.

    (a) In General.--Not later than one year after the date of the 
enactment of this Act, the Secretary of Health and Human Services, 
acting through the Administrator of the Centers for Medicare & Medicaid 
Services (referred to in this section as the ``Administrator''), shall 
promulgate regulations requiring each direct-to-consumer advertisement 
on television (including broadcast, cable, streaming, and satellite 
television) for a prescription drug or biological product for which 
payment is available under title XVIII or XIX of the Social Security 
Act to include a textual statement, which shall be truthful and not 
misleading, indicating the list price, as determined on the first day 
of the quarter during which the advertisement is being aired or 
otherwise broadcast, for a typical 30-day regimen or typical course of 
treatment (whichever is most appropriate).

    (b) Determinations.--In promulgating regulations under subsection

    (a) , the Administrator shall determine--

    (1) whether such regulations should apply with respect to 
 additional forms of advertising;

    (2) the manner and format of textual statements described 
 in such subsection;

    (3) appropriate enforcement mechanisms; and

    (4) whether such textual statements should include any 
 other price information, as appropriate.
 <all>